Diarrhea
Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients
December 09, 2016Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.
A Systematic Review and Meta-analysis of the Risk of Diarrhea Associated With Vandetanib Treatment in Carcinoma Patients
July 21, 2016[OncoTargets and Therapy] This research examines overall risks of all-grade and high-grade diarrhea during vandetanib treatment, to gain a better understanding of its prediction and management.
Diarrhea management in patients with rectal cancer
July 14, 2014What are the best forms of management for diarrhea in patients with rectal cancer?
Fidaxomicin to treat C. difficile-tied diarrhea in cancer
June 10, 2013Higher cure and sustained response rates, shorter time to resolution of diarrhea versus vancomycin
Assessing and treating radiotherapy-associated diarrhea
February 22, 2013A common side effect of cancer treatment, including radiotherapy, is diarrhea. Treatment is based on its cause and severity.
Sign Up for Free e-newsletters
ONA Articles
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Risk of Relapse Up for Young Adults With Leukemia
- Influence of Surgical Options for Early-Stage Lung Cancer on Opioid Use
- Affordable Care Act Has Positive Impact on Outcomes Among Those With Head and Neck Cancer
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Advances in Radiogenomics: A Review
- LDR-BT Boost Plus EBRT, ADT Improves Survival in High-Risk Prostate Cancer
- Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC
- Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer
- Frequency of Reclassifications of Genetic Testing Results Is Low
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |